ORNBV Orion Oyj Class B

Orion Corporation's financial reporting and Annual General Meeting in 2021

Orion Corporation's financial reporting and Annual General Meeting in 2021

ORION CORPORATION          STOCK EXCHANGE RELEASE           17 JULY 2020 at 9.30 EEST             

         

Orion Corporation's financial reporting and Annual General Meeting in 2021 

 

Orion Corporation will publish its Financial Statement Release 2020 on Tuesday, 9 February 2021.

The publication dates of the Interim Reports and the Half-Year Financial Report in 2021 are as follows:

Interim Report January-March 2021 

Half-Year Financial Report January-June 2021

Interim Report January-September 2021
 Tuesday, 27 April 2021

Monday, 19 July 2021

Wednesday, 20 October 2021



The Financial Statements and the Report of the Board of Directors for 2020 will be published on the Company's website at the latest in week 9/2021.

The Annual General Meeting is planned to be held on Thursday, 25 March 2021 in Helsinki.



Orion's financial reports and related presentation material are available on the Group's website at promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. 

Orion Corporation

Timo Lappalainen

President and CEO
 Olli Huotari

SVP, Corporate Functions
 

                                                                                                                                   

Contact person:

Tuukka Hirvonen, Investor Relations

tel. 1

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland





Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

EN
17/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

337,000 Orion Corporation A shares converted into B shares

337,000 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at 9.00 EEST         337,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 337,000 A shares have been converted into 337,000 B shares. The conversion has been entered into the Trade Register on 20 August 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,...

 PRESS RELEASE

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         20.8.2025 KLO 9.00          337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 337 000 A-osaketta 337 000 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 20.8.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 31 971 783 kpl ja B-osakkeita 109 162 495 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä...

Orion Oyj: 1 director

A director at Orion Oyj sold 4,000 shares at 64.481EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation: Managers’ transactions – Juhani Kankaanpää ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST         Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Juhani KankaanpääPosition...

 PRESS RELEASE

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää ORION OYJ        JOHTOHENKILÖIDEN LIIKETOIMET         8.8.2025 KLO 9.30          Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää Orion Oyj on saanut seuraavan Markkinoiden väärinkäyttöasetuksen (EU) N:o 596/2014 mukaisen ilmoituksen johtohenkilön tai johtohenkilön lähipiirin liiketoimista Orionin osakkeilla tai muilla Orioniin liittyvillä rahoitusvälineillä. Orion Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Juhani KankaanpääAsema: Muu ylin johtoLiikkeeseenlaskija: Or...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch